Patents by Inventor Patrice Hugo

Patrice Hugo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8541173
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: September 24, 2013
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Privé, Kamran Shazand
  • Publication number: 20120208869
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Application
    Filed: February 23, 2012
    Publication date: August 16, 2012
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Privé, Kamran Shazand
  • Patent number: 8148061
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: April 3, 2012
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Privé, Kamran Shazand
  • Publication number: 20070269434
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-041 expression or activity, comprising: contacting a candidate compound with a TAT-041 and detecting the presence or absence of binding between said compound and said TAT-041, or detecting a change in TAT-041 expression or activity. Methods are also included for the identification of compounds that modulate TAT-041 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-041 expression or activity.
    Type: Application
    Filed: January 31, 2007
    Publication date: November 22, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070220620
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-046 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-046 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-046 expression or activity, comprising: contacting a candidate compound with a TAT-046 and detecting the presence or absence of binding between said compound and said TAT-046, or detecting a change in TAT-046 expression or activity. Methods are also included for the identification of compounds that modulate TAT-046 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-046 expression or activity.
    Type: Application
    Filed: January 31, 2007
    Publication date: September 20, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070192885
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-039 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-039 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-039 expression or activity, comprising: contacting a candidate compound with a TAT-039 and detecting the presence or absence of binding between said compound and said TAT-039, or detecting a change in TAT-039 expression or activity. Methods are also included for the identification of compounds that modulate TAT-039 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-039 expression or activity.
    Type: Application
    Filed: January 26, 2007
    Publication date: August 16, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070192887
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity.
    Type: Application
    Filed: January 30, 2007
    Publication date: August 16, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070192884
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity.
    Type: Application
    Filed: January 25, 2007
    Publication date: August 16, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070192883
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-028 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-028 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-028 expression or activity, comprising: contacting a candidate compound with a TAT-028 and detecting the presence or absence of binding between said compound and said TAT-028, or detecting a change in TAT-028 expression or activity. Methods are also included for the identification of compounds that modulate TAT-028 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-028 expression or activity.
    Type: Application
    Filed: January 19, 2007
    Publication date: August 16, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070192886
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-044 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-044 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-044 expression or activity, comprising: contacting a candidate compound with a TAT-044 and detecting the presence or absence of binding between said compound and said TAT-044, or detecting a change in TAT-044 expression or activity. Methods are also included for the identification of compounds that modulate TAT-044 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-044 expression or activity.
    Type: Application
    Filed: January 30, 2007
    Publication date: August 16, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070186295
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-036 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-036 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-036 expression or activity, comprising: contacting a candidate compound with a TAT-036 and detecting the presence or absence of binding between said compound and said TAT-036, or detecting a change in TAT-036 expression or activity. Methods are also included for the identification of compounds that modulate TAT-036 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-036 expression or activity.
    Type: Application
    Filed: January 24, 2007
    Publication date: August 9, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070186294
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-030 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-030 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-030 expression or activity, comprising: contacting a candidate compound with a TAT-030 and detecting the presence or absence of binding between said compound and said TAT-030, or detecting a change in TAT-030 expression or activity. Methods are also included for the identification of compounds that modulate TAT-030 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-030 expression or activity.
    Type: Application
    Filed: January 19, 2007
    Publication date: August 9, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20070180545
    Abstract: Surprisingly, the present inventors have discovered that expression of TAT-031 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-031 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-031 expression or activity, comprising: contacting a candidate compound with a TAT-031 and detecting the presence or absence of binding between said compound and said TAT-031, or detecting a change in TAT-031 expression or activity. Methods are also included for the identification of compounds that modulate TAT-031 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-031 expression or activity.
    Type: Application
    Filed: January 19, 2007
    Publication date: August 2, 2007
    Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
  • Publication number: 20060057584
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Application
    Filed: August 17, 2004
    Publication date: March 16, 2006
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Prive, Kamran Shazand
  • Patent number: 6777182
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: August 17, 2004
    Assignee: Metriogene Biosciences Inc.
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Privé, Kamran Shazand
  • Patent number: 6743595
    Abstract: The invention relates to a method and a kit for the diagnosis of endometriosis using blood and endometrial leukocyte markers or a combination thereof. The marker is a surface antigen from endometrial or blood leukocytes.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: June 1, 2004
    Assignee: Metriogene Biosciences Inc.
    Inventors: Diane Gosselin, Danièle Gagné, Patrice Hugo, Pierre Miron
  • Publication number: 20030219835
    Abstract: The invention relates to methods and a kit for the diagnosis of endometriosis. More particularly, the invention relates to the measurement of endometrial leukocytes bearing CD16b and, optionally, other leukocyte or serous markers, for determining likelihood of suffering from endometriosis in a female subject.
    Type: Application
    Filed: February 12, 2003
    Publication date: November 27, 2003
    Applicant: Metriogene Biosciences Inc.
    Inventors: Diane Gosselin, Daniele Gagne, Martin Page, Michele Rivard, Christele Platon, Manon Lepine, Kamran Shazand, Patrice Hugo
  • Publication number: 20020127555
    Abstract: The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.
    Type: Application
    Filed: February 26, 2001
    Publication date: September 12, 2002
    Inventors: Soheyl Baban, Monique Bernard, Elana Cherry, Diane Gosselin, Patrice Hugo, Brigitte Malette, Pierre Miron, Charles Prive, Kamran Shazand